NeoGenomics (NEO) Competitors $16.92 +0.09 (+0.53%) (As of 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NEO vs. HQY, BILI, QXO, ETSY, MARA, LYFT, TNET, DXC, CARG, and ALITShould you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include HealthEquity (HQY), Bilibili (BILI), QXO (QXO), Etsy (ETSY), MARA (MARA), Lyft (LYFT), TriNet Group (TNET), DXC Technology (DXC), CarGurus (CARG), and Alight (ALIT). These companies are all part of the "business services" industry. NeoGenomics vs. HealthEquity Bilibili QXO Etsy MARA Lyft TriNet Group DXC Technology CarGurus Alight NeoGenomics (NASDAQ:NEO) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Is NEO or HQY more profitable? HealthEquity has a net margin of 8.41% compared to NeoGenomics' net margin of -12.07%. HealthEquity's return on equity of 9.70% beat NeoGenomics' return on equity.Company Net Margins Return on Equity Return on Assets NeoGenomics-12.07% -2.11% -1.18% HealthEquity 8.41%9.70%6.08% Does the media favor NEO or HQY? In the previous week, NeoGenomics had 4 more articles in the media than HealthEquity. MarketBeat recorded 5 mentions for NeoGenomics and 1 mentions for HealthEquity. NeoGenomics' average media sentiment score of 1.12 beat HealthEquity's score of 0.78 indicating that NeoGenomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthEquity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer NEO or HQY? NeoGenomics presently has a consensus price target of $20.30, suggesting a potential upside of 23.93%. HealthEquity has a consensus price target of $110.71, suggesting a potential upside of 15.18%. Given NeoGenomics' higher possible upside, analysts clearly believe NeoGenomics is more favorable than HealthEquity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeoGenomics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91HealthEquity 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk and volatility, NEO or HQY? NeoGenomics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Does the MarketBeat Community favor NEO or HQY? HealthEquity received 30 more outperform votes than NeoGenomics when rated by MarketBeat users. However, 70.85% of users gave NeoGenomics an outperform vote while only 70.04% of users gave HealthEquity an outperform vote. CompanyUnderperformOutperformNeoGenomicsOutperform Votes50370.85% Underperform Votes20729.15% HealthEquityOutperform Votes53370.04% Underperform Votes22829.96% Which has preferable earnings & valuation, NEO or HQY? HealthEquity has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoGenomics$644.12M3.26-$87.97M-$0.61-26.85HealthEquity$1.15B7.24$55.71M$1.0988.18 Do insiders and institutionals have more ownership in NEO or HQY? 98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 99.6% of HealthEquity shares are owned by institutional investors. 1.3% of NeoGenomics shares are owned by insiders. Comparatively, 2.2% of HealthEquity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryHealthEquity beats NeoGenomics on 13 of the 18 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get NeoGenomics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEO vs. The Competition Export to ExcelMetricNeoGenomicsTesting laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.10B$3.02B$5.16B$8.99BDividend YieldN/A1.55%4.96%4.20%P/E Ratio-26.85N/A87.2417.02Price / Sales3.262.691,137.12120.43Price / Cash62.8038.3743.2737.84Price / Book2.222.654.814.91Net Income-$87.97M$106.45M$120.16M$225.21M7 Day Performance-0.91%0.93%1.17%3.27%1 Month Performance-7.61%0.23%16.27%1.80%1 Year Performance1.24%-29.00%28.43%16.50% NeoGenomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEONeoGenomics1.8791 of 5 stars$16.92+0.5%$20.30+20.0%+4.0%$2.17B$644.12M-27.742,100Positive NewsHQYHealthEquity3.0401 of 5 stars$96.15+1.3%$110.71+15.1%+45.2%$8.33B$1.15B88.213,150BILIBilibili1.6428 of 5 stars$19.20-2.0%$19.69+2.6%+54.8%$7.96B$25.45B-20.878,801Short Interest ↑QXOQXO2.5021 of 5 stars$15.22-1.4%N/AN/A$6.23B$56.84M-1.67195Short Interest ↓Positive NewsETSYEtsy4.4113 of 5 stars$55.29-2.7%$63.17+14.3%-35.0%$6.22B$2.80B28.212,420MARAMARA3.527 of 5 stars$19.22-3.7%$25.80+34.2%-21.5%$6.19B$387.51M24.339Short Interest ↑LYFTLyft4.5895 of 5 stars$13.68+0.8%$17.77+29.9%-11.2%$5.67B$4.40B-85.502,945Short Interest ↑TNETTriNet Group3.9139 of 5 stars$89.49-0.6%$117.00+30.7%-24.0%$4.44B$4.97B17.243,600Short Interest ↑Negative NewsDXCDXC Technology2.277 of 5 stars$20.89+1.4%$20.890.0%-11.7%$3.78B$13.26B261.16130,000CARGCarGurus3.5242 of 5 stars$35.91-0.3%$37.86+5.4%+53.4%$3.72B$888.97M-78.061,343ALITAlight3.7061 of 5 stars$6.78-1.2%$10.83+59.8%-19.0%$3.68B$3.36B-14.1218,000 Related Companies and Tools Related Companies HealthEquity Alternatives Bilibili Alternatives QXO Alternatives Etsy Alternatives MARA Alternatives Lyft Alternatives TriNet Group Alternatives DXC Technology Alternatives CarGurus Alternatives Alight Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEO) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
